Zoetis Inc. (NYSE:ZTS) Shares Acquired by SevenBridge Financial Group LLC

SevenBridge Financial Group LLC increased its stake in shares of Zoetis Inc. (NYSE:ZTS) by 44.3% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 3,237 shares of the company’s stock after purchasing an additional 993 shares during the period. SevenBridge Financial Group LLC’s holdings in Zoetis were worth $564,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of ZTS. Mission Wealth Management LP raised its holdings in shares of Zoetis by 2.0% in the 4th quarter. Mission Wealth Management LP now owns 2,938 shares of the company’s stock valued at $479,000 after purchasing an additional 59 shares in the last quarter. VeraBank N.A. increased its holdings in Zoetis by 4.1% in the fourth quarter. VeraBank N.A. now owns 1,562 shares of the company’s stock valued at $254,000 after buying an additional 62 shares during the last quarter. HUB Investment Partners LLC raised its stake in Zoetis by 4.7% in the fourth quarter. HUB Investment Partners LLC now owns 1,373 shares of the company’s stock valued at $224,000 after buying an additional 62 shares in the last quarter. Procyon Advisors LLC lifted its holdings in Zoetis by 1.4% during the 4th quarter. Procyon Advisors LLC now owns 4,712 shares of the company’s stock worth $768,000 after buying an additional 63 shares during the last quarter. Finally, Deseret Mutual Benefit Administrators boosted its position in shares of Zoetis by 6.6% during the 4th quarter. Deseret Mutual Benefit Administrators now owns 1,045 shares of the company’s stock worth $170,000 after acquiring an additional 65 shares in the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Stock Down 1.7 %

Zoetis stock opened at $161.77 on Wednesday. The stock has a market capitalization of $72.44 billion, a price-to-earnings ratio of 29.57, a PEG ratio of 2.78 and a beta of 0.94. The company has a current ratio of 1.75, a quick ratio of 1.08 and a debt-to-equity ratio of 1.09. The stock has a 50 day moving average of $166.26 and a two-hundred day moving average of $174.05. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $200.33.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, beating analysts’ consensus estimates of $1.37 by $0.03. The firm had revenue of $2.32 billion for the quarter, compared to analyst estimates of $2.30 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. As a group, research analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be issued a dividend of $0.50 per share. The ex-dividend date of this dividend is Monday, April 21st. This represents a $2.00 annualized dividend and a yield of 1.24%. Zoetis’s dividend payout ratio is currently 36.56%.

Insider Activity at Zoetis

In other news, EVP Roxanne Lagano sold 326 shares of the stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $170.00, for a total transaction of $55,420.00. Following the completion of the transaction, the executive vice president now directly owns 15,781 shares of the company’s stock, valued at approximately $2,682,770. This represents a 2.02 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Willie M. Reed sold 1,210 shares of Zoetis stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total value of $201,029.40. Following the completion of the sale, the director now owns 11,245 shares in the company, valued at approximately $1,868,244.30. This trade represents a 9.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 1,862 shares of company stock worth $312,254 over the last 90 days. Company insiders own 0.16% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently weighed in on ZTS. Stifel Nicolaus decreased their target price on Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a research note on Tuesday, January 7th. StockNews.com upgraded shares of Zoetis from a “hold” rating to a “buy” rating in a research report on Friday, March 7th. UBS Group started coverage on shares of Zoetis in a research report on Monday, December 9th. They issued a “neutral” rating and a $196.00 target price on the stock. Piper Sandler lifted their price target on shares of Zoetis from $200.00 to $205.00 and gave the stock an “overweight” rating in a research note on Thursday, February 27th. Finally, Barclays upped their price objective on shares of Zoetis from $242.00 to $244.00 and gave the company an “overweight” rating in a research note on Friday, February 14th. One equities research analyst has rated the stock with a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $215.90.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.